RARRES2 and breast cancer: Clinical information analysis suggested a potential pro-tumorigenic effect of chemerin in breast cancer, as demonstrated by the fact that the overall survival (OS) rate of patients expressing higher levels of chemerin was worse than that of those expressing lower levels [132].